News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Articles|July 31, 2025

Psychotherapy: July Special Report Recap

Author(s)Jessica Walters

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

schizophrenia

Psychotherapy and the Prevention of Relapse in Schizophrenia

ByMark L. Ruffalo, MSW, DPsa,Trisha M. Ruffalo, MSW

May 21st 2026

Advances in Ketamine-Assisted Psychotherapy

ByFernando Espí Forcén, MD, PhD

May 19th 2026

brain

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

ByJoseph F. Goldberg, MD,Holly A. Swartz, MD

May 1st 2026

ai chatbot psychotherapy

Psychotherapies Can No Longer Afford to Compete With Each Other

ByAllen Frances, MD,Deven Dees

April 28th 2026

psychotherapy

To Be or Not to Be…Congruent

ByDennis Palumbo, MA, MFT

April 17th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD